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In a clinical trial of cerebral palsy, the level of plasma interleukin-8 (IL-8) was increased, correlated 
with motor improvement, after human umbilical cord blood mononuclear cell (hUCBC) infusion. This 
study aimed to elucidate the role of IL-8 in the therapeutic effects of hUCBCs in a mouse model of 
hypoxic-ischaemic brain injury (HI). In P7 HI mouse brains, hUCBC administration at day 7 after HI 
upregulated the gene expression of Cxcl2, the mouse IL-8 homologue and increased the expression 
of its receptor, CXCR2. hUCBC administration restored the sequential downstream signalling axis of 
p-p38/p-MAPKAPK2, NFκB, and angiogenic factors, which were downregulated by HI. An in vitro assay 
revealed the downregulation of the angiogenic pathway by CXCR2 knockdown and p38 inhibition. 
In vivo p38 inhibition prior to hUCBC administration in HI mouse brains produced identical results. 
Behavioural outcomes revealed a therapeutic effect (ps < 0.01) of hUCBC or IL-8 administration, which 
was correlated with decreases in infarct size and angiogenic findings in the striatum. In conclusion, the 
response of the host to hUCBC administration in mice upregulated Cxcl2, which led to the activation 
of the IL-8-mediated p-p38 signalling pathway. The upregulation of the downstream pathway and 
angiogenic growth factors via NFκB can be inferred to be the potential therapeutic mechanism of 
hUCBCs.
Cerebral palsy is the most common cause of severe motor disability that exists throughout life from the early 
childhood period and is attributed to injury in the developing brain1,2. Perinatal hypoxic-ischaemic brain injury 
(HI) is the main pathology of cerebral palsy3. Although therapeutic hypothermia is a currently available treatment 
for near-term infants with HI4, the possibility of disability or death remains high, ranging from 31% to 55%5, 
requiring adjuvant therapy to improve the outcome. For the treatment of sequelae after HI, cell therapy with 
human umbilical cord blood mononuclear cells (hUCBC) has shown some efficacy in preclinical and clinical 
studies6,7. While several mechanisms underlying the effects of hUCBCs, including cytokine production8 have 
been suggested9,10, a recent clinical study revealed a significant increase in plasma interleukin-8 (IL-8) levels in 
hUCBC-treated subjects. The IL-8 elevation at 12 days after the treatment showed a definite correlation with the 
improvement of gross motor function 6 months later11.
Human IL-8 is a neutrophil chemoattractant that binds to transmembrane G-protein-coupled chemokine 
receptors 1 and 2 (CXCR1, 2)12. Multiple processes that are essential for angiogenesis, endothelial cell prolifer-
ation, and capillary tube organization are mediated by IL-813,14. It is noteworthy that the response to injury in 
the developing brain is different from that in the adult brain with continuing inflammation, which exacerbates 
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brain damage for years after the initial insult15. Thus, the implications of neuroprotection are more important for 
young HI victims, with a close relationship to angiogenesis16. IL-8 exerts a neuroprotective function by producing 
growth factors17, inhibiting apoptosis18, and modulating synaptic transmission19 in brain cells.
Based on previous studies on the stimulation of angiogenesis by stem cells via an IL-8-mediated pathway, 
a study was designed to determine the effect of hUCBCs on angiogenesis and neuroprotection in a mouse HI 
model. In the translation of the clinical study, mice at postnatal day 7 were selected to replicate a mean age of 
3.5 years11 for hUCBC administration after HI. The following potential signalling molecules in the IL-8-related 
angiogenic pathway were included in the experiment: Cxcl2, a representative mouse homologue of IL-8; CXCR2, 
the transmembrane receptor for IL-8; p38 mitogen-activated protein kinase (MAPK); and the transcription 
factor nuclear factor kappa B (NFκB). It was found that VEGF-driven actin-based motility required p38 acti-
vation20 and that p38 inhibition enhanced abnormal endothelial hyperplasia in bFGF-induced neovasculariza-
tion21. Additionally, the signalling of angiogenic genes such as VEGF, platelet-derived growth factor (PDGF), 
and bFGF was found to be related to NFκB22,23. In this study, IL-8-mediated p38 MAPK signalling and angi-
ogenic gene expression following hUCBC administration were examined in HI mouse brain tissue in vivo and 
in mouse microvascular endothelial cells in vitro. The upregulation of the angiogenic genes and the endothelial 
marker CD31 in conjunction with NFκB activation was also investigated to establish the therapeutic mechanism 
of hUCBCs. In addition, the therapeutic effect of hUCBCs was evaluated through behavioural assessments and 
brain infarct size measurements in comparison with other treatments after HI. Thus, HI control, cyclosporine 
(CsA)-, hUCBC-, and IL-8-treated groups were included in this study. Cyclosporine was used as an adjuvant for 
the suppression of the host immune response in hUCBC-treated mice.
Results
Human UCB mononuclear cells upregulate CXCR2 and p38 phosphorylation and induce the 
subsequent degradation of IκB in the HI mouse brain. In mice, the gene encoding IL-8 has been 
deleted24, and murine Cxcl2 is a functional homologue of IL-8. Mice exhibit a receptor homologous to human 
CXCR2 that is able to mediate signal transduction in response to human IL-825,26. To determine whether murine 
Cxcl2 and its receptor, CXCR2, are upregulated by hUCBC administration in a mouse HI model, RT-PCR and 
Western blotting were performed. The Cxcl2 mRNA level was increased in the brains of HI mice subjected to 
hUCBC injection according to RT-PCR results (Fig. 1a). The upregulation of Cxcl2 expression 1 h after hUCBC 
injection was consistently noted via real-time PCR (p < 0.01) (Fig. 1b), and it continued until 1 day after injection 
(data not shown). In addition, the expression levels of CXCR2 and its downstream kinase p-p38 were upregulated 
following the upregulation of Cxcl2 by hUCBC administration in the HI model (Fig. 1c,d).
Most MAPK and phosphoinositide 3-kinase (PI3K) pathways are reported to be neuroprotective signalling 
pathways27. Within these pathways, extracellular signal-regulated kinase (Erk)-MAPK 1/2, the PI3K effector ser-
ine/threonine kinase Akt, and p38 MAPK are suggested to transduce IL-8 signals in angiogenesis28–30. Therefore, 
p-Erk 1/2 (T202/Y204), p-Akt (S473), and p-p38 (T180/Y182) were monitored as potential components of 
IL-8-mediated signalling pathways. The results showed that p-p38 (T180/Y182), which was initially downregu-
lated after HI, was increased significantly in response to hUCBC treatment (p < 0.05) (Fig. 1c,d); however, p-Erk 
1/2(T202/Y204) and p-Akt (S473) did not show any substantial change (Supplementary Fig. S1).
NFκB is involved in the downstream pathway of p38-mediated angiogenesis31. To evaluate whether NFκB 
is activated in response to p38 phosphorylation, the level of IκB was examined by Western blotting. The level of 
p-p38 was decreased after HI but was significantly increased by hUCBC administration (p < 0.05), whereas IκB 
showed the greatest increase during HI and then decreased after hUCBC administration in mouse hypoxic brain 
tissues (Fig. 1c,d). These data indicate the proximity of the p-p38 and NFκB pathways in the response to hUCBC 
administration and support the notion that the activation of the p38 pathway leads to subsequent NFκB activa-
tion via IκB degradation as a result of hUCBC administration.
Human UCB mononuclear cells upregulate the synthesis of the angiogenic growth factors 
VEGF, bFGF, and PDGF and the endothelial marker CD31 in the HI mouse brain. To con-
firm whether hUCBC administration upregulates angiogenesis in the brains of HI mice, the protein levels of 
VEGF, bFGF, PDGF, and CD31 were measured by Western blotting. All angiogenic growth factors that were 
initially downregulated after HI, were upregulated beginning on the first day after hUCBC injection (Fig. 2a–d). 
Significantly increased protein levels of PDGF were maintained up to 3 days post-hUCBC (p < 0.01), and the 
levels of VEGF and the endothelial marker CD31 increased significantly at 3 days post-hUCBC administration 
(ps < 0.05) (Fig. 2).
CXCR2 knockdown using siRNA transfection downregulates the IL-8-mediated angio-
genic pathway in vitro. To confirm the involvement of the IL-8 receptor CXCR2 in the angiogenic cas-
cade of downstream of IL-8, mouse brain endothelial bEnd.3 cells were transfected by CXCR2 siRNA. In the 
CXCR2-knockdown bEnd.3 cells, the IL-8-downstream molecules p-p38, p-MAPKAPK2, the angiogenic growth 
factors VEGF and bFGF, and the endothelial marker CD31 were all downregulated according to Western blot 
analysis, despite IL-8 treatment (p < 0.05) (Fig. 3a–i). The degradation of IκB, reflecting NFκB activation, was also 
measured to observe the effect on IL-8 in CXCR2-knockdown bEnd.3 cells. The activation of NFκB was found to 
be prevented by CXCR2 knockdown. Taken together, these findings may indicate that CXCR2 is responsible for 
IL-8 mediated angiogenesis through NFκB regulation.
Inhibition of p38 prior to hUCBC administration prevents angiogenic growth factors upregula-
tions and angiogenesis by hindering the downstream p38 pathway in the HI mouse brain. To 
evaluate whether the increased activity of p38 induced by hUCBC administration is involved in the upregulation 
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of angiogenic growth factors, SB203580 was employed for p38 inhibition in vivo. SB203580 is a specific inhibitor 
of p38α and p38β that suppresses the p38 MAPK stimulation of MAPKAPK2.
The phosphorylation of MAPKAPK2 induced by hUCBCs was blocked in mouse brain tissue using SB203580 
as a p38 inhibitor. The level of IκB, which is degraded to release NFκB for intranuclear transfer, showed a ten-
dency to increase after p38 inhibition, suggesting that NFκB activation is regulated by the p38 pathway (Fig. 4a,b). 
Western blot results for the angiogenic growth factors VEGF, bFGF, and PDGF and the direct endothelial marker 
CD31 showed a tendency to be downregulated in the brain tissue of mice treated with the p38 inhibitor SB203580 
prior to hUCBC administration (Fig. 4c–g). These in vivo p38 inhibition data suggest that hUCBC administration 
induces angiogenesis mediated by a p38-dependent pathway.
Inhibition of p38 in mouse endothelial cells prevents the IL-8-mediated upregulation of angio-
genic factors in vitro. To confirm the above in vivo results, the p38 inhibitor SB203580 was applied to mouse 
brain endothelial bEnd.3 cells. In response to human IL-8 treatment, p38 was immediately phosphorylated with 
a strong peak of phosphorylation being observed at 3 hours, and the phosphorylation signal was sustained up to 
6 h after stimulation (data not shown). As shown in Fig. 5, the phosphorylation of p38 was significantly increased 
in bEnd.3 cells harvested 3 h after IL-8 treatment (p < 0.05), while SB203580 reduced the phosphorylation of 
Figure 1. The effects of hUCBCs on the IL-8-mediated signalling pathway include the upregulation of Cxcl2 
and CXCR2 expression, p38 activation, and subsequent degradation of IκB in the HI mouse brain. (a) The 
mRNA level of mouse Cxcl2, the IL-8 homologue was upregulated at 1 h post-hUCBC treatment according 
to RT-PCR analysis of the HI mouse brain (n = 5). (b) The upregulation of Cxcl2 expression after hUCBC 
administration in the HI mouse brain was consistent and significant according to real-time PCR assays 1 h post-
hUCBC injection (n = 7). (c) The levels of mouse CXCR2 (the receptor for Cxcl2), p-p38, IκB, and ß-actin in 
the sham, HI, and hUCBC groups sacrificed on post-hUCBC days 1 and 3 were assayed using Western blotting 
to observe the consecutive changes after Cxcl2 upregulation. The level of CXCR2 was upregulated in parallel 
with p38 activation and the successive degradation of IκB after hUCBC administration. (d) The graph depicts 
the band intensity in p-p38 Western blotting. The data were obtained from triplicate results. Data are shown as 
the mean ± SEM (n = 5). Asterisks (*) indicate significant differences (*p < 0.05, **p < 0.01, one-way ANOVA) 
between groups. HI, hypoxic-ischaemic brain injury; hUCBCs, human umbilical cord blood mononuclear cells; 
UCB, HI mice subjected to hUCBC treatment.
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p38 and MAPKAPK2. In addition, the nuclear translocation of NFκB was increased and maintained for 6 h in 
oxygen-glucose deprivation (OGD)-conditioned cells following IL-8 treatment (Supplementary Fig. S2) 
(p < 0.05), whereas this response was inhibited by SB203580 according to immunocytochemistry (p < 0.05) 
(Fig. 5c,d). A significant reduction in angiogenic growth factors and CD31 was observed after p38 inhibition 
30 min prior to IL-8 administration according to Western blotting (ps < 0.05) (Fig. 5e–i). Taken together, the data 
indicate that the IL-8-mediated p38 pathway induces angiogenesis in vivo, which was confirmed in vitro using 
vascular endothelial cells.
Upregulation of angiogenesis is observed in mouse brains treated with hUCBCs or IL-8 upon 
immunohistochemistry in vivo. The density of vessels (percentage) expressing VEGF and CD31 was 
markedly decreased in the HI mouse brain, which was recovered one week after either hUCBC or IL-8 treatment. 
The density of vessels expressing VEGF was increased significantly by both hUCBC and IL-8 injection (p < 0.001) 
compared to the HI control, whereas CD31 expression was increased significantly only by hUCBC administration 
(p < 0.01) (Fig. 6). The angiogenic effect of hUCBCs was confined to the affected brain hemisphere. The density 
of vessels in the unaffected contralateral hemisphere of mice in the sham group was not significantly different 
compared with that in the other groups (Supplementary Fig. S3).
These results were supported by in vitro experiments in bEnd.3 cells showing an increase in the MMP9 
enzymatic activity signal (greatest under 50 ng/ml IL-8 treatment) and tube formation after IL-8 treatment 
(Supplementary Figs. S4 and S5).
Functional improvement in hUCBC or IL-8-treated HI mice occurred in parallel with improved 
cell viability and a reduced of infarct volume. Functional performance assessed by using the modified 
neurological severity score (mNSS) and the cylinder test showed significant improvement in the hUCBC- or 
IL-8-treated groups compared with the HI-only control and CsA groups at 7 weeks after HI (ps < 0.01) (Fig. 7a,b). 
These results were consistent with the attenuation of brain damage in vivo. Cresyl violet staining of the brains 
of mice sacrificed after behavioural tests revealed a substantial decrease in the infarct volume as well as signif-
icantly greater cell viability in the hUCBC- and IL-8-treated groups comparison with the HI and CsA groups 
(ps < 0.0001) (Fig. 7c–e).
Figure 2. Effects of hUCBCs on the IL-8-mediated upregulation of angiogenic growth factors and the 
endothelial marker CD31. The affected brain hemispheres of HI mice sacrificed 1 day after hUCBC 
administration were collected for Western blot analysis. (a) The protein levels of angiogenic growth factors 
VEGF, bFGF, and PDGF, and the endothelial marker CD31 were all downregulated after HI and then 
significantly recovered after hUCBC administration according to Western blotting. (b–e) The graphs depict 
the band intensity in each Western blot assay. Data are shown as the mean ± SEM (each n ≥ 5). The data 
were collected from triplicate results. Asterisks (*) indicate significant differences (*p < 0.05, **p < 0.01, 
***p < 0.001, one-way ANOVA). HI, hypoxic-ischaemic brain injury; hUCBC, human umbilical cord blood 
mononuclear cells; UCB, HI mice subjected to hUCBC treatment.
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Figure 3. CXCR2 knockdown via siRNA transfection in brain endothelial bEnd.3 cells resulted in reduced 
activation of the downstream angiogenic pathway. Brain endothelial bEnd.3 cells cultured in DMEM for 24 h 
were transfected with siRNA targeting CXCR2 (90 pmol) and incubated for 24 h. (a) CXCR2 knockdown 
resulted in the downregulation of IL-8-downstream p-p38, angiogenic growth factors, IκB degradation 
representing NFκB release, and CD31 (endothelial marker) according to Western blotting, despite IL-8 
treatment. (b–i) The graphs depict the band intensity in each Western blot assay. Data are shown as the mean 
± SEM (each n ≥ 3). The data were obtained from triplicate results. Asterisks (*) indicate significant differences 
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA). IL-8, bEnd.3 cells treated with IL-8 
without prior CXCR2 knockdown; siCXCR2+IL-8, CXCR2-knockdown bEnd.3 cells treated with IL-8.
Figure 4. In vivo effects of p38 inhibition on the IL-8-mediated angiogenic pathway in the HI mouse brain. 
(a) Mice treated with the p38 inhibitor SB203580 (0.25 mg/kg) 30 min prior to hUCBC injection showed a 
decrease in the levels of p-MAPKAPK2 and IκB in response to hUCBC treatment, despite an increase in p-p38 
after hUCBC injection according to Western blotting. (b) The graph depicts the band intensity of p-p38. (c) The 
protein levels of the angiogenic growth factors VEGF, bFGF, and PDGF and the endothelial marker CD31 were 
all downregulated following p38 inhibition according to Western blotting. (d–g) The graphs depict the band 
intensity in each Western blot assay. Data are shown as the mean ± SEM (each n ≥ 3). The data shown in the 
graphs were obtained from triplicate results. Asterisks (*) indicate significant differences (*p < 0.05, one-way 
ANOVA). HI, hypoxic-ischaemic brain injury; hUCBCs, human umbilical cord blood mononuclear cells; UCB, 
HI mice subjected to hUCBC treatment; UCB+SB, mice treated with SB203580 prior to hUCBC treatment.
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Discussion
In this study, we demonstrated that hUCBCs induced the activation of an IL-8-mediated angiogenic cascade in 
a mouse HI model. Following hUCBC administration, the upregulation of the IL-8 homologue Cxcl2 and its 
receptor CXCR2, the phosphorylation of the downstream molecules p38 and MAPKAPK2, the degradation of 
IκB, leading to NFκB activation, and the upregulation of angiogenic growth factors and the endothelial marker 
CD31 all occurred in a consecutive manner beginning on the next day. The therapeutic effect of hUCBCs was 
ascertained according to behavioural outcomes 35 d later, and the results paralleled the in vivo attenuation of 
brain injury.
Human IL-8 is a small, soluble peptide (8–10 kDa) secreted by nonimmune cells as well as monocytes and 
macrophages32. In mice, two functional homologues of human IL-8 (keratinocyte-derived chemokine (Cxcl1) and 
macrophage inflammatory protein (Cxcl2)) are present24–26,33,34. Cxcl2 and CXCR2 were evaluated as the mouse 
IL-8 homologue and the receptor for the IL-8 family, respectively, in this study. hUCBC administration resulted 
in an increase in the Cxcl2 levels in HI mice, similar to the increase in the IL-8 levels observed in hUCBC-treated 
Figure 5. Effects of p38 inhibition in vitro on IL-8-mediated angiogenic growth factor expression in mouse 
brain vascular bEnd.3 cells. (a) A significant increase in p-p38 was noted after IL-8 treatment (50 ng/ml), while 
SB203580 (50 μM) application 30 min prior to IL-8 administration decreased p-MAPKAPK2 levels according 
to Western blot analysis of OGD-conditioned bEnd.3 cells. (b) The graph depicts the band intensity of p-p38 
in the Western blot assay. Data are shown as the mean ± SEM (each n = 5). (c) The proportion of merged p65- 
and DAPI-stained cells was significantly greater at 6 h after IL-8 treatment than in the OGD-only control cells 
and p38-inhibited cells upon immunocytochemistry analysis (200×). (d) The graph depicts the proportion 
of merged p65 and DAPI-stained cells. Data are shown as the mean ± SEM (each n = 4). (e–i) Westerns blot 
analysis of cells harvested 12 h after IL-8 treatment showed the upregulation of VEGF, bFGF and PDGF and 
the endothelial marker CD31, whereas cells pretreated with SB203580 exhibited the downregulation of the 
angiogenic growth factors and CD31, as shown in the graphs depicting the band intensity. Data are shown as 
the mean ± SEM (each n ≥ 4). The data shown in the graphs were collected from triplicate results. Asterisks 
(*) indicate significant differences (*p < 0.05, **p < 0.01, one-way ANOVA) according to Tukey’s multiple 
comparisons between groups. OGD, oxygen-glucose deprivation; Green, p65; DAPI, 4′, 6-diamidino-2-
phenylindole for nuclear staining; Control, bEnd.3 cells without IL-8 treatment; IL-8+SB, SB203580 infused 
prior to IL-8 administration.
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patients, which was correlated with motor function improvement11. Murine Cxcl2 elevation in the HI mouse 
brain after intraperitoneal hUCBC administration suggests a host response via the secretion of Cxcl2 by mouse 
cells. The host response of Cxcl2 production and downstream angiogenic cascade activation in the brain could be 
the driving forces in hUCBC therapy.
A systemic host response to the infusion of hUCBCs has also been reported in other studies. In Alzheimer’s 
disease model mice, the intravenous infusion of hUCBCs increases the levels of anti-inflammatory cytokines in 
plasma and reduces the level of circulating sCD40L, an important mediator of inflammation35. In a rat stroke 
model study, intravenous hUCBC injection induced a strong immunomodulatory reaction in the host via inhib-
iting splenic cytotoxic T cell release in association with an increase in anti-inflammatory IL-10 secretion and a 
reduction in pro-inflammatory cytokine levels36.
Figure 6. Effects of hUCBCs and IL-8 on angiogenesis in vivo in the HI mouse brain. Angiogenesis was 
observed in vivo through immunohistochemistry staining for VEGF and CD31 in the peri-infarct cortex 
and striatum of HI mice dissected one week after either hUCBC (3 × 107/kg) or IL-8 (50 µg/kg) injection. 
(a,c) The graph depicts the density of vessels (percentage) expressing VEGF among all cells stained with 
DAPI according to IHC analysis in the ipsilesional and contralateral hemispheres. (b,d) The graph depicts 
the percentage of vessel density expressing CD31 among DAPI-stained cells observed in the lesion side and 
unaffected contralateral hemispheres. On the other hand, the unaffected contralateral brain hemisphere was 
not significantly affected by HI, hUCBC or IL-8 administration. IHC findings of the contralateral hemisphere 
are depicted in Supplementary Fig. S3. Data are shown as the mean ± SEM (each n = 3). Asterisks (*) indicate 
significant differences (*p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA) according to Tukey’s multiple 
comparisons between groups. HI, hypoxic-ischaemic brain injury; DAPI, 4′, 6-diamidino-2-phenylindole for 
nuclear staining; +UCB, HI mice subjected to hUCBC treatment; +IL-8, HI mice subjected to IL-8 treatment; 
hUCBCs, human umbilical cord blood mononuclear cells.
8Scientific RepoRtS |         (2020) 10:4446  | https://doi.org/10.1038/s41598-020-61441-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
The receptor for IL-8 or Cxcl2, CXCR2 is present on the surface of endothelial cells37 and other types of 
cells, including leukocytes38, neurons39, and oligodendrocytes40. Human intestinal epithelial cells expressing 
CXCR2 show an IL-8-mediated angiogenic response41. In this study, the upregulation of CXCR2 was consist-
ently observed following hUCBC administration in vivo or IL-8 treatment in vitro (Supplementary Fig. S6). 
Moreover, CXCR2-knockdown bEnd.3 cells exhibited the downregulation of all downstream components of the 
IL-8-mediated angiogenic pathway despite IL-8 treatment. This finding suggests that CXCR2 is responsible for 
the angiogenic effect of Cxcl2 (Fig. 3).
Among the pathways downstream of IL-8, the p38 MAPK pathway showed greater activation than the 
Erk or Akt pathway (Supplementary Fig. S1). The p38 MAPK pathway has been found to play an important 
Figure 7. Behavioural improvement after hUCBC or IL-8 injection parallels the attenuation of brain damage. 
HI mice treated with hUCBCs or IL-8 showed significant improvement of the mNSS and cylinder tests at P42 
in multiple comparisons with the sham, HI, and CsA-only groups. (a,b) The graphs depict mNSS scores and the 
percentage of impaired forelimb use in each group. Multiple comparisons of each group revealed no difference 
between the HI and CsA groups or among the sham, hUCBC and IL-8 groups. Data are shown as the mean ± 
SEM (each n ≥ 8). (c) Cresyl violet-stained brain coronal sections (above) were used for cell viability assessment 
of the affected brain cortex (below). (d–e) Each graph depicts the immunohistochemistry analysis of the 
infarct volume and viable cell counts. The reduction in infarct volume in the affected hemisphere was estimated 
in comparison to that in the contralateral side. Data are shown as the mean ± SEM (each n ≥ 3). Asterisks 
(*) indicate significant differences (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA) 
according to Tukey’s multiple comparisons between groups. mNSS, modified neurological severity score; HI, 
hypoxic-ischaemic brain injury; hUCBCs, human umbilical cord blood mononuclear cells; +CsA, HI mice 
subjected to cyclosporine-only treatment; +UCB, HI mice subjected to hUCBC treatment; +IL-8, HI mice 
subjected to IL-8 treatment.
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role in endothelial cell migration42, which is essential for angiogenesis, and the inhibition of p38 attenuated 
VEGF-induced cell migration20. Similarly, the present study revealed that hUCBC administration upregulated the 
expression of the p38-downstream molecule p-MAPKAPK2 and angiogenic growth factors, while p38 inhibition 
downregulated these responses to a level comparable to that observed under HI (Fig. 4). In addition to its angi-
ogenic effects, p38 activation has been reported to prompt neuronal differentiation43,44, axonal growth, dendritic 
differentiation, and increased neuronal survival45.
As a downstream target of the p38 pathway31, NFκB activation was followed in the present study. NFκB regu-
lates the degradation of the vascular basement membrane and the remodelling of the extracellular matrix, which 
is essential for angiogenesis46,47. The administration of hUCBCs reduced the level of IκB, indicating that NFκB 
activation was promoted by hUCBCs (Fig. 1c). Prior p38 inhibition increased the IκB level, implying that the 
activation of NFκB is dependent on the p38 pathway (Fig. 4a).
The changes in the protein levels of the angiogenic growth factors VEGF, PDGF, and bFGF in response to HI, 
hUCBC or IL-8 treatment were consistent in brain tissue and cell culture experiments (Figs. 2–6). The decline in 
angiogenic growth factor expression induced by p38 inhibition was more prominent in endothelial cells in vitro 
than in brain tissue in vivo. This difference could be caused by differences in the environment, such as variable cel-
lular components of brain tissues, rather than the bEnd.3 cell culture conditions alone. Alternatively, the vascular 
nature of bEnd.3 cells may have led to a stronger response.
One of the concerns in reproducing the corresponding clinical intervention in an experimental setting is 
related to the coadministration of immunosuppressant CsA48. To rule out any effect caused by CsA on therapeutic 
efficacy of hUCBCs or IL-8, we added another control group of HI mice treated only with CsA, which presented 
striking similarity to the HI group in contrast to the hUCBC or IL-8 groups in a multiple comparison analysis 
(ps < 0.01) (Fig. 7). This finding suggests that CsA has little influence in the course of hUCBC-prompted angio-
genesis or on therapeutic efficacy in clinical practice.
Finally, the ultimate therapeutic effect of hUCBCs or IL-8 was revealed by behavioural improvements with 
ameliorated brain damage, accompanied by increased angiogenic findings in the HI mouse brain. Furthermore, 
cell viability and blood vessel densities were increased at 35 d post-therapy, accompanied by functional improve-
ments under both hUCBC and IL-8 treatments. The levels of angiogenic growth factors and CD31 were increased 
by hUCBC treatment to the same or greater extent compared with IL-8 treatment in the mouse brain.
The current study has some limitations that need to be addressed in future research. First, the specific mech-
anism or cellular sources responsible for Cxcl2 elevation need to be determined. Second, it needs to be clarified 
which cells in the brain respond to IL-8 in humans or to its homologue in mice. Since the brain is a highly com-
plicated organ consisting of various cell types, the specific cells that exert neuroprotective effects among these 
cells should be further investigated. It has been reported that oligodendrocyte progenitor cells are protected from 
apoptosis via CXCR2 signalling49. Similarly, CXCR2 inhibits β-amyloid-induced hippocampal neuronal apop-
tosis50. Third, the relationship between Cxcl2 elevation and CXCR2 upregulation and the subsequent increase 
in p-p38 following hUCBC administration needs to be clarified to delineate the molecular pathway upstream of 
p38. A study involving CXCR2 gene knockout mice would be helpful to provide further evidence in this regard.
In conclusion, this study confirmed that the administration of hUCBCs after HI upregulates angiogenic gene 
expression and resultant angiogenesis via the Cxcl2-mediated activation of the p38 pathway as a host response. 
Taken together with the previous clinical study, these results indicate that hUCBC-induced IL-8-mediated angi-
ogenesis could be a key neuroprotective mechanism in the human HI brain.
Materials and Methods
Human umbilical cord blood was supplied by the CHA Medical Center cord blood bank. The cryopreserva-
tion of donated hUCBCs was performed following the protocol of the facility; white blood cell concentrates 
were generated via the Rubinstein method and treated with dimethylsulfoxide and dextran before freezing 
in a controlled-rate freezer, then cryopreserved in a freezer at −198° within 36 hours after collection51. All 
human-related protocols were approved by the Institutional Ethics Committee of CHA Bundang Medical Center. 
The number of total nucleated cells injected was 3 × 107/kg based on clinical trials in which this number of cells 
was used7. Briefly, the cells were prepared according to our protocol, in which the hUCBCs were thawed and then 
washed twice with a 1:1 solution of 5% albumin and 10% dextran to eliminate dimethyl sulfoxide51. The cells were 
subsequently dissolved in saline for injection.
Animals. To assess the effect of hUCBCs on the IL-8-mediated angiogenic pathway, newborn Institute 
of Cancer Research (ICR) mice of both sexes were used. All experimental protocols were approved by the 
Institutional Animal Care and Use Committee of CHA University (Approval no. 160079, 180181). All mice were 
housed and maintained according to the regulations of the committee.
The HI model was adapted from the Rice-Vannucci model52 with minor modifications. Briefly, at postnatal 
day 7 (P7), the right carotid artery of the HI mice was ligated with 5–0 nylon blue under isoflurane anaesthesia. 
Then, the mice were placed in a warm chamber, which was perfused with a hypoxic gas mixture (8% oxygen, 92% 
nitrogen) for 1 h. The mortality rate of the mice was approximately one in 30 mice. The extent of the lesion was 
assessed through the semitransparent skull following a scalp incision under isoflurane anaesthesia on P13. Mice 
exhibiting severe injury involving more than half of the ipsilateral hemisphere and those without any injury were 
excluded53. Therefore, mice with mild to moderate injury were included in the analysis.
The study groups included the sham, HI, hUCBC treatment, and IL-8 treatment groups. In the hUCBC group, 
HI mice were treated with hUCBCs (3 × 107 total nucleated cells/kg) at P14, 7 days post-HI. The immunosuppres-
sant CsA (10 mg/kg) was administered to the hUCBC group for 5 consecutive days beginning on P13, in place of 
the clinical procedures, and the same protocol was followed for the other experiments using hUCBCs. A single 
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injection of 50 µg/kg IL-8 was given once to HI mice at P14 on the same day as the hUCBC group. All materials 
injected into the mice were administered via the intraperitoneal route.
For evaluation of the sequential short-term molecular responses after hUCBC injection, ICR mice were ran-
domly allocated to sham (n = 5), HI (n = 5), and hUCBC treatment (n = 10) groups. The HI group and sham 
group were sacrificed at P13, and the hUCBC group mice were sacrificed at P15 (n = 5) or P17 (n = 5) to observe 
the changes after hUCBC administration (Figs. 1 and 2).
For the in vivo p38 inhibition experiment, additional HI mice were randomly assigned to the control (n = 4) 
and hUCBC (n = 8) groups. Half of the hUCBC group received the p38 inhibitor SB203580 (Cell Signaling 
Technology, MA, USA; 0.25 mg/kg) 30 min prior to hUCBC administration. Dimethyl sulfoxide (0.01%) was 
used to dilute SB203580, and the same amount of dimethyl sulfoxide was injected into the hUCBC group without 
p38 inhibition. All groups for p38 inhibition study were sacrificed at P17 (Fig. 4).
Other HI mice were randomly assigned to the control (n = 4), IL-8 (n = 4) or hUCBC (n = 4) treatment groups 
for visualization of in vivo angiogenesis through IHC staining. One week after this treatment, their brains were 
dissected for IHC (Fig. 6).
For behavioural assessment, another set of newborn mice was randomly assigned to the sham (n = 9), HI con-
trol (n = 8), CsA (n = 9), hUCBC (n = 9), and IL-8 (n = 8) treatment groups. Immediately after the behavioural 
assessments conducted at P42 (35 d after HI), all groups were sacrificed to evaluate the infarct volume and cell 
viability in the affected brain hemisphere (Fig. 7). A schematic timeline of the HI treatments, including hUCBC 
injection, is presented in Fig. 8.
Reverse transcription polymerase chain reaction (RT-PCR) and real-time PCR. The injured right 
hemispheres of the mouse brains were harvested and homogenized with TRIzol (Invitrogen) to extract total 
cellular RNA. ReverTra Ace qPCR RT Master Mix (Toyobo Co., Osaka, Japan) was used for cDNA synthesis. The 
primers for Cxcl2, a mouse homologue of IL-8, were Cxcl2 forward, 5′-CTCTCAAGGGCGGTCAAAAAGTT-3′, 
and Cxcl2 reverse, 5′-TCAGACAGCGAGGCACATCAGGTA-3′. Quantitative real-time PCR was performed in 
a CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The amount of 
RNA used was 100 ng.
Western blotting. Proteins were extracted from the affected hemisphere of the mouse brain using RIPA 
Lysis and Extraction Buffer (Thermo Fisher). The protein content of the brain tissue was quantified via the 
Bradford method according to the manufacturer’s instructions (Bio-Rad). Equal amounts (40 µg) of the samples 
were dissolved in SDS sample buffer and heated at 99 °C for 6 min. The samples were separated using SDS-PAGE 
and transferred to polyvinylidene difluoride membranes (Millipore, Bellerica, CA, USA). A 5% skimmed milk 
solution was used to block the membranes for 1 h at room temperature on a rocker. The housekeeping gene 
β-actin was employed as a loading control. Primary antibodies against IκB, bFGF, PDGF, and β-actin were pur-
chased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Antibodies against phosphorylated (p)-p38, 
p-MAPKAPK2, and p65 (NFKB) were purchased from Cell Signalling Technology (Danvers, MA, USA), 
while antibodies against CXCR2 and CD31 were purchased from Abcam (Cambridge, UK). The antibody for 
VEGF was purchased from Invitrogen and Novus Biologicals (Centennial, CO, USA). The primary target anti-
bodies were all diluted 1:1,000 and incubated with the membranes at 4 °C for 16 h (overnight). A horseradish 
peroxidase-conjugated anti-rabbit IgG antibody (Santa Cruz) at a dilution of 1:20,000 or an anti-mouse IgG 
antibody (KPL, Inc., Gaithersburg, MD, USA) at a dilution of 1:10,000 was added to the corresponding primary 
antibodies, followed by incubation for 1 h at room temperature. The membranes were developed with the ECL 
reagent (Millipore).
Figure 8. Schematic illustration of the timeline for the assessment of the effects of hUCBCs in ameliorating 
mouse brain lesions and behavioural outcomes. Postnatal day 7 (P7) ICR mice were conditioned for hypoxic-
ischaemic brain injury. Intraperitoneal cyclosporine was administered to the hUCBC group and cyclosporine-
only group beginning on P13 for 5 consecutive days (small arrows). At P14, the hUCBC group received 
hUCBCs (3 × 107/kg) intraperitoneally, whereas IL-8 group received IL-8 (50 µg/kg) intraperitoneally. For 
long-term follow-up, mice were allocated to the sham, HI, cyclosporine, hUCBC, and IL-8 groups. At P21, the 
sham, HI, hUCBC, and IL-8 groups were assessed for angiogenesis via IHC. At P42, behavioural test of the mice 
was performed prior to sacrifice. Sacrifice A: sacrifice schedule for inhibition tests; Sacrifice B: for IHC and 
behavioural studies; HI, hypoxic-ischaemic brain injury; hUCBC, human umbilical cord blood mononuclear 
cells; IHC, immunohistochemistry.
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Cells and cultures. In vitro cell cultures were generated using immortalized mouse brain endothelial bEnd.3 
cells, purchased from the ATCC (Manassas, VA, USA). The culture conditions for the bEnd.3 cells followed 
the manufacturer’s guidelines. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, 
Carlsbad, CA, USA) supplemented with 10% foetal bovine serum (FBS, Sigma-Aldrich, Germany) and 1% pen-
icillin and streptomycin. The cells were treated with human recombinant IL-8 (IL-8, Thermo Fisher Scientific, 
Pittsburgh, PA, USA; 50 ng/ml) in 6-well plates until reaching 70% confluence. The cells were then harvested after 
3 h for RT-PCR and Western blotting.
As the IL-8-mediated proliferation of endothelial cells has been reported to be dose and time dependent13, 
variable harvesting times and titres were tested in cells cultured in DMEM with FBS. The results showed the 
greatest cell viability under an IL-8 dose of 50 ng/ml (Supplementary Fig. S7).
To determine the role of the IL-8 receptor CXCR2 on the IL-8-downstream angiogenic pathway, bEnd.3 cells 
were transfected with small interfering RNAs (siRNAs) specific to CXCR2 manufactured by Thermo Fisher (PA, 
USA). CXCR2 siRNA sequences targeting the sense strand, 5′-GAACCAAGCUGAUCAAGGATT-3′, and the 
antisense strand, 5′-UCCUUGAUCAGCUUGGUUCTC-3′, were used. Appropriate concentrations (approxi-
mately 60–80%) of bEnd.3 cells cultured in DMEM for 24 h were plated in 6-well plates. Then, siRNA targeting 
CXCR2 was transfected at a 90 pmol concentration using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. After 24 h of incubation, IL-8 was added. The knockdown of CXCR2 
in bEnd.3 cells was determined via RT-PCR.
To determine whether intracellular signalling through the p-p38 pathway is critical for IL-8-mediated angi-
ogenesis in vitro, mouse endothelial bEnd.3 cells were treated with the p38 inhibitor SB203580 (50 μM) 30 min 
prior to IL-8 (50 ng/ml) administration. Cells were harvested at 12 h post-IL-8 treatment, as maximal angiogenic 
gene expression was observed at 12 h post-IL-8 administration.
Immunocytochemistry. The facilitation of intranuclear NFκB translocation, as a component of angio-
genic signalling was demonstrated in bEnd.3 cells exposed to 24 h of OGD prior to IL-8 (50 ng/ml) treatment. 
For hypoxic cell conditioning, cells were subjected to 24 h of OGD under 5% CO2 and 95% N2 prior to human 
recombinant IL-8 (50 ng/ml) exposure. The cellular response after OGD was observed by comparing the results 
of treatment with phosphate-buffered saline (PBS) as a control to those of IL-8 treatment; the two cell groups 
were harvested at the identical time point of 12 h posttreatment. Cells plated in 2-well chamber slides were rinsed 
twice with PBS and then fixed in 4% paraformaldehyde. After additional rinses in PBS, the cells were blocked 
with PBS in 2% normal goat serum with 1% Triton X-100 blocking solution for 1 h. Primary antibodies specific 
to p65 were used as a marker of NFκB expression. A mounting solution with 4′, 6-diamidino-2-phenylindole 
(DAPI) was employed. A fluorescence microscope (Eclipse Ts2, Nikon Inc., Tokyo, Japan) was used to observe 
and photograph the cells.
Immunohistochemistry. Mice treated with either IL-8 or hUCBCs 7 days after HI were dissected 14 
days after injury. Isoflurane anaesthetized mice were intracardially perfused with 30 ml of saline followed by 
30 ml of 4% paraformaldehyde. Their dissected brains were fixed overnight and cryoprotected in 30% sucrose. 
Coronal sections (10 µm) were serially collected throughout the brain and mounted on glass slides: every slide 
was assessed for histology and IHC.
The tissues were then washed in PBS and incubated for 1 h in blocking solution (2% normal goat serum, 0.5% 
Triton, PBS). The tissues were subsequently incubated for 24 h with the following primary antibodies: rabbit 
anti-CD31 (1:50, Abcam) and mouse anti-VEGF (1:100, Novus Biologicals). Thereafter, fluorescence-conjugated 
secondary antibodies (1:1,000, Alexa 488-conjugated goat anti-rabbit, Alexa Fluor 594 goat anti-mouse) were 
incubated with the tissue sections for 1 h at room temperature. After the sections had been washed, they were 
mounted in ProLong Gold reagent with DAPI (Molecular Probes, Invitrogen). To estimate vessel density, the 
number of vessels formed was measured using the ImageJ program after an image was obtained by fluorescence 
microscopy at 200× magnification.
Behavioural study. The neurological function of mice was assessed using the mNSS and the cylinder test54. 
Neurological function was graded on a scale of 0–14 (normal score: 0; maximal deficit score: 14). The cylinder 
test was performed to assess the functional asymmetry of the forepaw. Mice were placed in a transparent Plexiglas 
cylinder (diameter: 20 cm, height: 30 cm), and the number of contacts of each forepaw with the cylinder wall was 




impaired forepaw contact no





+ − + .
×
.
Cresyl violet staining. Mice sacrificed after behavioural tests at 5 weeks after HI were dissected in the same 
manner indicated above. Coronal brain sections of 10 µm were prepared using a cryostat and stained with 0.5% 
cresyl violet. Images of each cresyl violet-stained brain slice was obtained under a light microscope (Nikon, 
Japan). The number of cells was counted for determination of cell viability using the ImageJ program. For infarct 
volume, the infarct area in the affected hemisphere was measured in comparison to that of contralateral hemi-
sphere in the identical location by ImageJ program.
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Statistical analysis. The significance of the data was determined via one-way ANOVA and Tukey’s post hoc 
test for multiple comparison analysis using SPSS software (IBM, Chicago, IL, USA) and Prism 8.0 (GraphPad 
Software Inc., San Diego, CA, USA). A value of p < 0.05 was considered significant.
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